AEON Biopharma (NYSE American: AEON) named John Bencich as Chief Financial Officer and granted inducement equity awards on April 2, 2026. The Compensation Committee approved 754,717 RSUs vesting 25% annually over four years (starting March 9, 2026) and 235,849 PSUs tied to NYSE American compliance.
PSU vesting: 25% at six months after NYSE American notifies the company of regained compliance, then 25% on each of the first three anniversaries of that date, subject to continued service and plan terms.
Loading...
Loading translation...
Positive
754,717 RSUs granted to CFO, vesting over four years
235,849 PSUs align CFO incentives with NYSE compliance milestone
Negative
PSU vesting contingent on NYSE American compliance could delay reward realization
Large equity grants may be dilutive depending on total outstanding share count
News Market Reaction – AEON
+2.39%
1 alert
+2.39%Session close to close
$22.49MMarket Cap
1.2xRel. Volume
In the Apr 6 session, AEON gained 2.39%, reflecting a moderate positive market reaction.
This announcement details equity inducement grants for the newly appointed CFO, including 754,717 RS...
Analysis
This announcement details equity inducement grants for the newly appointed CFO, including 754,717 RSUs and 235,849 PSUs tied partly to regaining NYSE American listing compliance. It follows earlier disclosures of sizeable equity awards to other executives and ongoing listing and capital structure challenges. Investors may focus on how these incentives align management with milestones around ABP-450’s development, balance sheet repair, and compliance deadlines outlined in recent 8-K and 10-K filings.
BPD Type 2a FDA meeting and shareholder approval enabling PIPE and note exchange.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has often been positive on development and financing, yet price reactions have been mixed, with several constructive updates followed by negative moves.
Recent Company History
Over the last few months, AEON has focused on its ABP-450 biosimilar program, regulatory interactions, and balance sheet repair. Updates included FDA BPD Type 2a feedback, an AAN abstract on analytical comparability, and shareholder approval of November transactions, plus a PIPE and note exchange reducing debt. Leadership changes, including appointing a new CFO, have also featured. Despite these milestones, price reactions have alternated between gains and pullbacks, underscoring uncertainty around execution and capital needs.
Key Terms
restricted stock units, performance-based restricted stock units, nyse american, continued listing standards, +3 more
7 terms
restricted stock unitsfinancial
"approved the grant to Mr. Bencich of 754,717 restricted stock units (“RSUs”)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance-based restricted stock unitsfinancial
"approved the grant to Mr. Bencich of 235,849 performance-based restricted stock units"
Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.
nyse americanregulatory
"Inducement Grants Under NYSE American LLC Company Guide Section 711"
NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.
continued listing standardsregulatory
"regained compliance with NYSE American’s continued listing standards"
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.
vestingfinancial
"The RSUs vest over four years, 25% on each annual anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement awardsfinancial
"Compensation Committee ... approved the grant of inducement awards"
Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.
employment inducement incentive award planfinancial
"under AEON’s 2025 Employment Inducement Incentive Award Plan"
An employment inducement incentive award plan is a program that gives new hires upfront or time‑based rewards—often company stock, options or cash—designed to persuade talent to join and stay. Think of it as a signing bonus that vests over time to align the new employee’s interests with the company’s future performance. Investors care because these awards create ongoing costs and can dilute existing ownership, while shaping management incentives and retention.
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the grant of inducement awards.
The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units (“RSUs”) under AEON’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which provides for the granting of equity awards to new employees of the Company. The RSUs vest over four years, 25% on each annual anniversary of March 9, 2026, which was Mr. Bencich’s employment start date. In addition, the Compensation Committee approved the grant to Mr. Bencich of 235,849 performance-based restricted stock units (“PSUs”) under the Inducement Plan. The PSUs will vest as follows: 25% will vest on the date that is six months following the date on which NYSE American notifies the Company that is has successfully regained compliance with NYSE American’s continued listing standards (the “First Vesting Date”) and an additional 25% will vest on each of the first, second and third anniversaries of the First Vesting Date, subject to Mr. Bencich’s continued service through the applicable vesting date.
The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement or PSU agreement, as applicable, covering the grant. The awards are being granted as an inducement material to Mr. Bencich entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.
AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of botulinum toxin products. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to continue to meet continued stock exchange listing standards; (ii) the Company’s ability to comply with the NYSE American approved plan to regain compliance with continued listing standards; and (iii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact: Laurence Watts New Street Investor Relations +1 619 916 7620 laurence@newstreetir.com
Source: AEON Biopharma
FAQ
What inducement awards did AEON (AEON) grant to its new CFO on April 2, 2026?
The company granted 754,717 RSUs and 235,849 PSUs as inducement awards to the CFO. According to the company, RSUs vest 25% annually over four years and PSUs vest based on NYSE American compliance milestones.
When do the 754,717 RSUs for AEON CFO begin vesting and what is the schedule?
RSUs begin vesting on March 9, 2026, with 25% vesting each year for four years. According to the company, March 9, 2026 was the CFO's employment start date used for the vesting schedule.
How are the 235,849 PSUs for AEON CFO tied to NYSE American compliance?
PSUs vest 25% six months after NYSE American notifies regained compliance, then 25% on each of three anniversaries. According to the company, vesting is subject to continued service and plan terms.
Does AEON state any service condition for the CFO’s RSU and PSU vesting?
Yes. Both RSU and PSU awards require the CFO's continued service through each applicable vesting date. According to the company, awards are subject to the Inducement Plan and grant agreements.
Why did AEON grant inducement awards under Section 711 of NYSE American Company Guide?
The grants were made as an inducement material to the CFO entering employment, consistent with Section 711. According to the company, the awards were approved by the Compensation Committee on April 2, 2026.
